Osimertinib (Tagrisso, AstraZeneca) demonstrated superior efficacy compared with platinum therapy plus pemetrexed (Alimta, Lilly) in patients with T790M-positive advanced non-small cell lung cancer (NSCLC) whose disease progressed during first-line epidermal growth factor receptor and tyrosine kinase inhibitor (EGFR-TKI) therapy (N Engl J Med 2016 Dec 6. [Epub ahead of print], PMID: 27959700).
DECEMBER 28, 2016